INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Globus Medical, Inc.

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors, following disappointing financial results for Q1 2025 that led to a significant drop in stock price [1][3]. Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, which was $0.06 below consensus estimates [3]. - The company's revenue for Q1 2025 was $598.12 million, missing consensus estimates by $27.78 million and reflecting a 1.4% decline year-over-year [3]. - Following the announcement of these results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to softer deal closures in Enabling Technology, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].